Most patients with pancreatic ductal adenocarcinoma (PDAC) present with symptomatic,
surgically unresectable disease. Although the goal of early detection of PDAC is laudable …

Pancreatic cancer is one of the solid tumors with the worst prognosis. Five-year survival rate
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …

Background The optimal nutritional therapy in the field of pancreatic surgery is still debated.
Methods An international panel of recognized pancreatic surgeons and pancreatologists …

It has frequently been shown that patients with cancer are one of the largest hospital patient
groups with a prevalence for malnutrition. Weight loss is a frequent manifestation of …

Introduction Pancreatic and periampullary adenocarcinomas are associated with abnormal
body composition visible on CT scans, including low muscle mass (sarcopenia) and low …

Importance Sarcopenia and sarcopenic obesity have been associated with poor outcomes
in unresectable pancreatic cancer (PC). Neoadjuvant treatment (NT) is used increasingly to …

Background & aims Sarcopenia, a loss of muscle mass, quality and function, which is
particularly evident in respiratory muscles, has been associated with many clinical adverse …

Background Numerous studies have suggested an association between sarcopenia in
pancreatic cancer and adverse outcomes. This systematic review examines the evidence for …

Background Sarcopenia and low skeletal muscle radiodensity (SMD) have been associated
with adverse outcomes in patients with colorectal cancer (CRC); however, factors …

Background: Patients with pancreatic cancer often develop cancer cachexia, a complex
multifactorial syndrome with weight loss, muscle wasting and adipose tissue depletion with …